These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37276599)

  • 1. Genotype-guided drug prescribing vs. usual care reduced clinically relevant adverse drug reactions at 12 wk.
    Holbrook AM
    Ann Intern Med; 2023 Jun; 176(6):JC70. PubMed ID: 37276599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
    Swen JJ; van der Wouden CH; Manson LE; Abdullah-Koolmees H; Blagec K; Blagus T; Böhringer S; Cambon-Thomsen A; Cecchin E; Cheung KC; Deneer VH; Dupui M; Ingelman-Sundberg M; Jonsson S; Joefield-Roka C; Just KS; Karlsson MO; Konta L; Koopmann R; Kriek M; Lehr T; Mitropoulou C; Rial-Sebbag E; Rollinson V; Roncato R; Samwald M; Schaeffeler E; Skokou M; Schwab M; Steinberger D; Stingl JC; Tremmel R; Turner RM; van Rhenen MH; Dávila Fajardo CL; Dolžan V; Patrinos GP; Pirmohamed M; Sunder-Plassmann G; Toffoli G; Guchelaar HJ;
    Lancet; 2023 Feb; 401(10374):347-356. PubMed ID: 36739136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a multi-gene pharmacogenetic panel reduces adverse drug effects.
    Cavallari LH; Johnson JA
    Cell Rep Med; 2023 May; 4(5):101021. PubMed ID: 37084734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype-guided drug prescribing: a systematic review and meta-analysis of randomized control trials.
    Goulding R; Dawes D; Price M; Wilkie S; Dawes M
    Br J Clin Pharmacol; 2015 Oct; 80(4):868-77. PubMed ID: 25060532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimising Adverse Drug Reactions and Verifying Economic Legitimacy-Pharmacogenomics Implementation in Children (MARVEL- PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation.
    Conyers R; Halman A; Moore C; Stenta T; Felmingham B; Collier L; Khatri D; Spelman T; Williams E; Dyas R; Kotecha RS; Jessop S; Mateos MK; Swen J; Elliott DA
    BMJ Open; 2024 May; 14(5):e085115. PubMed ID: 38760050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
    Cavallari LH; Beitelshees AL; Blake KV; Dressler LG; Duarte JD; Elsey A; Eichmeyer JN; Empey PE; Franciosi JP; Hicks JK; Holmes AM; Jeng L; Lee CR; Lima JJ; Limdi NA; Modlin J; Obeng AO; Petry N; Pratt VM; Skaar TC; Tuteja S; Voora D; Wagner M; Weitzel KW; Wilke RA; Peterson JF; Johnson JA
    Clin Transl Sci; 2017 May; 10(3):143-146. PubMed ID: 28294551
    [No Abstract]   [Full Text] [Related]  

  • 7. Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?
    Huddart R; Sangkuhl K; Whirl-Carrillo M; Klein TE
    Clin Pharmacol Ther; 2019 Aug; 106(2):284-286. PubMed ID: 30977517
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs.
    Zhang Z; Wu Y; Tan NC; Jiang Y
    Epileptic Disord; 2019 Aug; 21(4):330-336. PubMed ID: 31403464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
    Becquemont L
    Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.
    Lee YM; Danahey K; Knoebel RW; Ratain MJ; Meltzer DO; O'Donnell PH
    Pharmacogenet Genomics; 2019 Feb; 29(2):23-30. PubMed ID: 30531378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of actionable pharmacogenetic variants and high-risk drug prescriptions: A Swiss hospital-based cohort study.
    Hodel F; De Min MB; Thorball CW; Redin C; Vollenweider P; Girardin F; Fellay J
    Clin Transl Sci; 2024 Sep; 17(9):e70009. PubMed ID: 39263940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using pharmacogenetics to prevent severe adverse reactions to capecitabine.
    García-González X; López-Fernández LA
    Pharmacogenomics; 2017 Aug; 18(13):1199-1213. PubMed ID: 28746000
    [No Abstract]   [Full Text] [Related]  

  • 13. A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.
    Plumpton CO; Roberts D; Pirmohamed M; Hughes DA
    Pharmacoeconomics; 2016 Aug; 34(8):771-93. PubMed ID: 26984520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
    Shah RR
    Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
    Dunnenberger HM; Crews KR; Hoffman JM; Caudle KE; Broeckel U; Howard SC; Hunkler RJ; Klein TE; Evans WE; Relling MV
    Annu Rev Pharmacol Toxicol; 2015; 55():89-106. PubMed ID: 25292429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.
    Hicks JK; El Rouby N; Ong HH; Schildcrout JS; Ramsey LB; Shi Y; Anne Tang L; Aquilante CL; Beitelshees AL; Blake KV; Cimino JJ; Davis BH; Empey PE; Kao DP; Lemkin DL; Limdi NA; P Lipori G; Rosenman MB; Skaar TC; Teal E; Tuteja S; Wiley LK; Williams H; Winterstein AG; Van Driest SL; Cavallari LH; Peterson JF;
    Clin Pharmacol Ther; 2021 Jul; 110(1):179-188. PubMed ID: 33428770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation.
    Roden DM; Van Driest SL; Wells QS; Mosley JD; Denny JC; Peterson JF
    Circ Res; 2018 Apr; 122(9):1176-1190. PubMed ID: 29700066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for a cluster randomised controlled trial to determine the effectiveness and cost-effectiveness of independent pharmacist prescribing in care homes: the CHIPPS study.
    Bond CM; Holland R; Alldred DP; Arthur A; Barton G; Blyth A; Desborough J; Ford J; Handford C; Hill H; Hughes CM; Maskrey V; Massey K; Myint PK; Norris N; Poland FM; Shepstone L; Turner D; Zermansky A; Wright D;
    Trials; 2020 Jan; 21(1):103. PubMed ID: 31964398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping.
    Schildcrout JS; Denny JC; Bowton E; Gregg W; Pulley JM; Basford MA; Cowan JD; Xu H; Ramirez AH; Crawford DC; Ritchie MD; Peterson JF; Masys DR; Wilke RA; Roden DM
    Clin Pharmacol Ther; 2012 Aug; 92(2):235-42. PubMed ID: 22739144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facilitating clinical implementation of pharmacogenomics.
    Mrazek DA; Lerman C
    JAMA; 2011 Jul; 306(3):304-5. PubMed ID: 21771991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.